GC Labcell Turns Profitable in Q2 with 2.5 Billion KRW Operating Profit

[Asia Economy, reporter: Cho Hyun] GC Labcell announced in a provisional disclosure on July 28 that its consolidated operating profit for the second quarter of this year reached 2.5 billion KRW, turning a profit compared to the same period last year.

Revenue was 20 billion KRW, marking a 33.3% increase year-on-year. Net profit rose by 1,520.4% to 2.4 billion KRW.

GC Labcell explained that balanced growth across all business sectors drove both expansion in scale and improved profitability.

The specimen testing business segment grew by 27.4%, as COVID-19 specimen testing continued to increase. Sales from GCCL, its consolidated subsidiary responsible for the bio-logistics business and clinical trial specimen analysis, also grew by 21.1% and 22.9%, respectively.

Profitability improved significantly, driven by cost improvements and the partial recognition of technology transfer fees from Artiva, which is responsible for local development of the NK cell therapy in the United States.

A GC Labcell representative stated, "We expect the trend of improved performance to continue in the second half of the year, due to management efficiency measures and the ongoing impact of COVID-19."

This content was produced with the assistance of AI translation services.